|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Parkinson’s News Today
Gain Therapeutics cleared to start GT-02287 Phase 1 trial in Australia
|
Precision Medicine Online
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
|
BioWorld
Gain Therapeutics receives Australian HREC approval to begin phase I study of GT-02287 for GBA1-Parkinson’s disease
|
Nasdaq
Gain Therapeutics: Tackling Rare Diseases at the Genetic Level
|
Parkinson’s News Today
Oral therapy GT-02287 shows promise in Parkinson’s mice models
|
The Authority Magazine
The Future Is Now: Matthias Alder Of Gain Therapeutics On How Their Technological Innovations Will Shake Up The Tech Scene
|
BioSpace
Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease
|
Parkinsons News Today
STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s
|
Neurology Live
A New Approach to Protein Misfolding in Parkinson Disease
|
Parkinsons News Today
Small Molecules, STARs Treat Cell Models of GBA1-linked Parkinson’s
|
Benzinga
Gain Therapeutics' SEE-Tx™ Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding
|
Medscape Medical News
Positive Topline Results for Novel Parkinson's Treatment
|
BioTalk
BioTalk with Rich Bendis
|
US News
Direct Listing vs. IPO
|
RareDaily
Gain Therapeutics Raises $40M in IPO to Advance Rare Disease Pipeline
|
Nasdaq
Lysosomal storage disorder biotech Gain Therapeutics prices IPO at $11 midpoint
|
pm360
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors
|
Pharmaceutical Technology
Treating lysosomal storage disorders: Gain and Sumitomo Dainippon enter partnership
|
BioWorld
Gain Therapeutics Inc. signs a collaboration with Sumitomo Dainippon Pharma Co. Ltd.
|
BioSpace
Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
|
Proactive
Gain Therapeutics finalizing animal proof-of-concept study in Parkinson's Disease
|